Online citations, reference lists, and bibliographies.

Importance Of Intensive Blood Pressure Control In Type 2 Diabetes: Mechanisms, Treatments And Current Guidelines

M. Marre
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Observational and interventional studies have shown that intensified blood pressure (BP) reduction can benefit people with diabetes. Because of their special haemodynamic properties, renin‐angiotensin‐aldosterone system (RAAS) blockers are recommended. The results of the BP arm of the ADVANCE study strongly support the recently updated European Society of Cardiology/European Association of Diabetes recommendations for the treatment of BP in people with diabetes, which recommend a target systolic/diastolic BP of 130/80 mmHg with few exceptions, and a fixed combination of an RAAS blocker with a diuretic or a calcium channel blocker as first‐line treatment.
This paper references
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B. Brenner (2001)
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
J. Stamler (1993)
Predicting diabetic nephropathy in insulin-dependent patients.
C. Mogensen (1984)
Doxazosin therapy in the treatment of diabetic hypertension.
M. Feher (1991)
Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients.
Charlyne Carpentier (2018)
T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes
A. Nicolas (2017)
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
S. Schinner (2009)
Dual renin–angiotensin system blockade and outcome benefits in hypertension: a narrative review
J. Mann (2015)
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
K. J. Schjoedt (2006)
Eplerenone in patients with systolic heart failure and mild symptoms.
F. Zannad (2011)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
M. Fischereder (2016)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
L. Hansson (1998)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
V. Perkovic (2019)
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
B. Pitt (2000)
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
M. Marre (1988)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg (2018)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C. Wanner (2016)
Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.
I. Gouni-Berthold (2017)
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS‐III trial
C. Funck-Brentano (2011)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
D. Z. I. Cherney (2014)
Canagliflozin and cardiovascular and renal events in type 2 diabetes
R. Guthrie (2018)
Inherited Disorders of the Renal Tubule
A. Bonnardeaux (2012)
Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.
M. Hallab (1993)
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
C. Emdin (2015)
Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.
J. Ménard (1997)
Basal insulin and cardiovascular and other outcomes in dysglycemia.
H. Gerstein (2012)
2018 ESC/ESH Guidelines for the management of arterial hypertension.
B. Williams (2018)
Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension.
Effects of beta-blockers on glucose and lipid metabolism
VA Fonseca (2010)
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
R. Zatz (1986)
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study
S. E. Nielsen (2012)
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
S. Zoungas (2014)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
K. Fox (2003)
Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.
T. Patente (2015)
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
K. Ayers (2012)
The Italian Microalbuminuria Study
IDDM (1998)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
A. Patel (2008)
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
A. Norhammar (2019)
The insulin receptor and the kidney
L. Hale (2013)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
S. Inzucchi (2017)
Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes
K. Mohammedi (2014)
Effects of Lisinopril and Nifedipine on the Progression to Overt Albuminuria in IDDM Patients With Incipient Nephropathy and Normal Blood Pressure
G. Crepaldi (1998)
The effect of spironolactone on morbidity and 40 MARRE mortality in patients with severe heart failure
B Pitt (1999)
Mechanism of diuresis following acute modest hyperglycemia in the rat.
R. Blantz (1983)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Declare–Timi Investigators (2019)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
G. Bakris (2015)
Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases.
M. Marre (1998)
Effect of ramipril on the incidence of diabetes.
J. Bosch (2006)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Heart Outcomes Prevention Evaluation Study Investigators (2000)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
J. Green (2015)
The effect of insulin on renal sodium metabolism
R. DeFronzo (2004)
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
M. Marre (2004)
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
J. Lovshin (2014)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
J. Staessen (1997)
Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control.
D. Sandeman (1992)
Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis
CA Emdin (2015)
Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
S. Bangalore (2011)
The missing link: a single unifying mechanism for diabetic complications.
T. Nishikawa (2000)
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
D. Wald (2009)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
M. R. Stearne (1998)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock (2019)
A new equation to estimate glomerular filtration rate.
A. Levey (2009)
Effects of inhibition of ATP-sensitive potassium channels on metabolic vasodilation in the human forearm.
H. Farouque (2003)
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
Effect of valsartan on the incidence of diabetes and cardiovascular events.
J. McMurray (2010)
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
C. Mogensen (2000)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
Prospective Studies Collaboration (2002)
Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients
T. Wascher (2005)
Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study.
Y. Noda (2000)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock (2019)
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans‐Henrik Parving (2012)
Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002)
S. Lewington (2003)
Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes
G. Velho (2015)
Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes
K. Mohammedi (2015)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
J. Wright (2015)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
F. Cosentino (2019)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study Group (1998)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
J. Staessen (1997)
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
B. Scirica (2013)
Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.
B. Brenner (1982)
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
G. P. Fadini (2018)
Diuretic and natriuretic effects of nifedipine on isolated perfused rat kidneys.
M. Marre (1982)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
J. F. Mann (2008)
Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes
Klaus K. Witte (2017)
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
R. Holman (2008)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
S. Lewington (2002)
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
H. L. Heerspink (2016)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
A. Fournier (1994)
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
R. Wing (2011)
Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials
W. Elliott (2010)
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
T. Ninomiya (2009)
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
H. Arima (2014)
Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
J. Skov (2016)
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
W. White (2013)
Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.
P. Winocour (1987)
Salt-sensitivity of proximal reabsorption alters macula densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus.
V. Vallon (2002)
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
M. G. Wulffelé (2004)
Telmisartan, ramipril, or both in patients at high risk for vascular events.
S. Yusuf (2008)
[A randomized trial of intensive versus standard blood pressure control].
J. A. Divisón Garrote (2016)
Effect of modest hyperglycemia on tubuloglomerular feedback activity.
R. Blantz (1982)
Nitric oxide in the normal kidney and in patients with diabetic nephropathy
P. Tessari (2014)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
E. Lewis (1993)
Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.
M. Marre (1987)
Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes
K. Mohammedi (2013)
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
C. Pyke (2014)
Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
J. Forbes (2008)
Heart Outcomes Prevention
Investigators Study (2000)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. Wiviott (2019)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
L. Correia (2016)
Gating and blocking of calcium channels by dihydropyridines in the pancreatic B-cell.
F. Malaisse-Lagae (1984)
Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial.
J. Staessen (1998)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel (2007)
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Edmund J. Lewis (2001)
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
P. Grant (2019)
How to cite this article: Marre M. Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines
Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes.
K. Mohammedi (2016)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri
B. Dahlöf (2005)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar